Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAD-1: Liraglutide Added to Glimepiride in Type 2 Diabetes
NCT00318422Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2006
- Primary completion
- May 2007
- Modality
- Peptides
- Countries
- 23
01
Overview
A Phase 3 trial of liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started May 2006; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00318422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00318422.